Search results
Results From The WOW.Com Content Network
Be sure that fire and carbon monoxide alarms are installed and working. Use technology to help you stay connected and keep track of your loved one’s whereabouts. Toa55/istockphoto. 7. Engage in ...
August 25, 2024 at 2:00 AM. After a lull of nearly 2 decades, the Food and Drug Administration (FDA) has approved some novel drugs for the treatment of Alzheimer’s disease since 2021. Most of ...
Rivastigmine (sold under the trade name Exelon among others) is a cholinesterase inhibitor used for the treatment of mild to moderate Alzheimer's disease. [6] The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, [7] which typically include nausea and vomiting.
Rapid eye movement behavior disorder occurs when there is a loss of normal voluntary muscle atonia during REM sleep resulting in motor behavior in response to dream content. It can be caused by adverse reactions to certain drugs or during drug withdrawal; however, it is most often associated with the elderly and in those with neurodegenerative ...
Neuropsychological tests are specifically designed tasks that are used to measure a psychological function known to be linked to a particular brain structure or pathway. [1] Tests are used for research into brain function and in a clinical setting for the diagnosis of deficits. They usually involve the systematic administration of clearly ...
People with dementia with Lewy bodies share many of the same symptoms of Alzheimer’s disease and Parkinson’s disease, including cognitive issues such as memory loss, problem-solving, and ...
Classification. Psychological therapies which are considered as potential treatments for dementia include music therapy, [5] reminiscence therapy, [6] cognitive reframing for caretakers, [7] validation therapy, [8] and mental exercise. [9] Interventions may be used in conjunction with pharmaceutical treatment and can be classified within ...
After 670 days, there were 1,172 new diagnoses of dementia among the study participants. When compared with people who took DPP-4 inhibitors, those who took SGLT-2 inhibitors had a 35 percent ...